Trials / Not Yet Recruiting
Not Yet RecruitingNCT04007276
The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients
The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Tulane University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | brimonidine tartrate ophthalmic solution 0.025% | Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface. |
| OTHER | sterile balanced saline solution | Single dose of sterile balanced saline solution applied as an eye drop to the eye surface. |
Timeline
- Start date
- 2026-11-10
- Primary completion
- 2031-06-01
- Completion
- 2036-06-01
- First posted
- 2019-07-05
- Last updated
- 2025-10-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04007276. Inclusion in this directory is not an endorsement.